Secondary metabolites will be extracted from a specific plant material to identify and isolate immune active components. These components are proposed to enhance the innate and adaptive immune systems by modulating certain cytokine levels in white blood cells before the progression of Human Immunodeficiency Virus (HIV) to Acquired Immune Deficiency Syndrome (AIDS) occurs. The components identified will be used to develop new anti-HIV immune-based therapies. The plant material containing the components with desirable immune active characteristics has been identified. The methods suitable for extraction of secondary metabolites (non-polymeric small molecules) from the plant material and antibody-based assay for testing of human cytokines in white blood cells have been established. Phase I of this project includes identification and isolation of immune active components from the plant extract using reverse phase High Performance Liquid Chromatography (HPLC), Ion-Exchange Chromatography (IEC), Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS). The percentage of active components in the plant will be determined. Phase II of the project will entail either large scale isolation/purification or synthesis of identified immune active plant components to develop screens for new anti-HIV immune-based therapies both in vitro and in vivo. The therapies proposed can reduce viral load and indirectly lower the resistance of HIV to current antiviral drugs.
Public Health Relevance: The project seeks to isolate immune active components from specific plants that can modulate certain cytokine levels in human white blood cells which would provide an immune-based therapeutic activity to attenuate HIV progression. The end result of this project would have substantial commercial potential as a frontline therapy and synergistic compound that can indirectly lower the resistance of HIV to current antiviral drugs. We believe that our potential product will be used either alone, as an initial therapy for newly diagnosed patients, or in combination with current antiviral drugs.
Thesaurus Terms: Aids; Aids Virus; Acquired Immune Deficiency; Acquired Immune Deficiency Syndrome; Acquired Immune Deficiency Syndrome Virus; Acquired Immuno-Deficiency Syndrome; Acquired Immunodeficiency Syndrome; Acquired Immunodeficiency Syndrome Virus; Address; Adverse Effects; Allergy; Anti-Retroviral Agents; Antibodies; Antiretroviral Agents; Antiviral Agents; Antiviral Drugs; Antivirals; Area; Assay; Attenuated; Bioassay; Biologic Assays; Biological Assay; Blood Leukocyte; Cells; Characteristics; Chemical Fractionation; Chromatography; Chromatography / Separation Science; Chromatography, High Performance Liquid; Chromatography, High Pressure Liquid; Chromatography, High Speed Liquid; Chromatography, Ion Exchange; Development; Disease; Disorder; Drug Resistance; Drugs; Effectiveness; Fracn; Fractionation; Fractionation Radiotherapy; Future; Generations; Goals; Hiv; Hplc; Htlv-Iii; High Pressure Liquid Chromatography; Human; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type Iii; Human T-Cell Lymphotropic Virus Type Iii; Human T-Lymphotropic Virus Type Iii; Human, General; Hypersensitivity; Il-15; Il15; Il15 Protein; Itx; Immune; Immune System; Immunologic Deficiency Syndrome, Acquired; Immunologically Directed Therapy; Immunotherapy; In Vitro; Interleukin-15; Interleukin-15 Precursor; Ion Exchange; Ion-Exchange Chromatography Procedure; Lav-Htlv-Iii; Leukocytes; Lymphadenopathy-Associated Virus; Mgc9721; Man (Taxonomy); Man, Modern; Marrow Leukocyte; Mass Spectrum; Mass Spectrum Analysis; Medical; Medication; Methods; Mutate; Newly Diagnosed; Nuclear Magnetic Resonance; Overdose; Patients; Pharmaceutic Preparations; Pharmaceutical Preparations; Phase; Photometry/Spectrum Analysis, Mass; Plant Components; Plant Extracts; Plant Structures; Plants; Plants, General; Production; Research; Resistance; Resistance Development; Resistant Development; Reticuloendothelial System, Leukocytes; Risk; Scheme; Science; Spectrometry, Mass; Spectroscopy, Mass; Spectrum Analyses, Mass; Spectrum Analysis, Mass; Testing; Therapeutic; Time; Toxic Effect; Toxicities; Treatment Side Effects; Viral; Viral Burden; Viral Load; Viral Load Result; Virus; Virus-Hiv; Viruses, General; White Blood Cells; White Cell; Anti-Retroviral; Antiretroviral; Base; Body System, Allergic/Immunologic; Commercialization; Cost; Cytokine; Cytokine Therapy; Developing Resistance; Disease/Disorder; Drug Resistant; Drug/Agent; Immune Therapy; In Vivo; New Therapeutics; Next Generation Therapeutics; Novel; Novel Therapeutics; Organ System, Allergic/Immunologic; Public Health Relevance; Resistance To Drug; Resistant; Resistant To Drug; Side Effect; Small Molecule; Soy; Therapy Adverse Effect; Treatment Adverse Effect; Vaccine Development; White Blood Cell; White Blood Corpuscle
